# A Study to Assess the Relative Bioavailability of 4 Formulations of Fentanyl Transdermal System Compared Against DUROGESIC Fentanyl Transdermal Patch After Single Application in Healthy Volunteers

> **NCT01717157** · PHASE1 · COMPLETED · sponsor: **Janssen Research & Development, LLC** · enrollment: 32 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Treatment A: DUROGESIC (8.4 mg fentanyl)
- **DRUG:** Treatment B: Transdermal System-Concept 1 (6.2 mg fentanyl)
- **DRUG:** Treatment C: Transdermal System-Concept 2 (6.2 mg fentanyl)
- **DRUG:** Treatment D: Transdermal System-Concept 3 (7.1 mg fentanyl)
- **DRUG:** Treatment E: Transdermal System-Concept 4 (11.0 mg fentanyl)

## Key facts

- **NCT ID:** NCT01717157
- **Lead sponsor:** Janssen Research & Development, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-08
- **Primary completion:** 2012-11
- **Final completion:** 2012-11
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2014-03-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01717157

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01717157, "A Study to Assess the Relative Bioavailability of 4 Formulations of Fentanyl Transdermal System Compared Against DUROGESIC Fentanyl Transdermal Patch After Single Application in Healthy Volunteers". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01717157. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*